Cancer History:

First diagnosis of cancer: 09/2013 Rhabdomyosarcoma (RMS) IIIa, cT2aN0M0

First recurrence date: 12/2013 sites: left posterior wall of the bladder about 34.5cm³

Refractory or persistent disease sites: left posterior wall of the bladder, recurrent tumors  invading the bladder and rectum

Therapy gone through: Surgery: Yes: 3 operations ; with minimal residual lesion Chemotherapy: 11 VAC/VTC; 8 VDC/IE and 2 CBVP; radiotherapy: 50.4Gy/28f

targeted drugs: no immunotherapy: no

Clinical Trial Number: NCT02992210 and NCT03356782 ;

enrolled date: 4/29/2015

Interventions: CART: 4SCAR-CD56

CRS Grade: 0 ; other side effects: nil

Treatment response: CR Quality of Life: Improved

Progression-free interval: 4_years 6_months

Current status: No evidence of disease

Publication, youtube, patient’s feedback letter:

DOI: 10.1097/MD.0000000000017572; PMID: 31651858

Medicine. 98(43):e17572, OCTOBER 2019

CD56–chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report

Chiyi Jiang;Wen Zhao;Maoquan Qin;Mei Jin;Lungji Chang;Xiaoli Ma

https://insights.ovid.com/crossref?an=00005792-201910250-00026